Abilita Hälsovård / Abilita Oy Ab
| Registration, return date of pre-test cases | Testing phases start date | Statement number and date | |
| Ongoing joint testings: | |||
| Functionality for action on behalf of a minor | 22.4.2020 | 1. Ongoing, 23.4.2020 2. Not tested 3. Not tested | |
| Accepted joint testings: | |||
| Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information | 20102016 / 30.12.2016 |
1 = Testing between system supplier and Kela, 2 = Testing between client test organisation and Kela, 3 = Cross-testing.
Acute / Acuvitec Oy
| Registration, return date of pre-test cases | Testing phases start date | Statement number and date | |
| Ongoing joint testings: | |||
| No ongoing joint testings | |||
| Accepted joint testings: | |||
| Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information | 20012016 / 30.11.2016 | ||
| Forward compatibility of the functionality to act on behalf of a minor | - / 17.2.2020 |
AssisDent / Entteri Professional Software Oy
| Registration, return date of pre-test cases | Testing phases start date | Statement number and date | |
| Ongoing joint testings: | |||
| No ongoing joint testings | |||
| Accepted joint testings: | |||
| Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information | 20062016 / 27.12.2016 | ||
| Forward compatibility of the functionality to act on behalf of a minor | - / 14.9.2020 |
DomaCare Medi / Invian Oy
| Registration, return date of pre-test cases | Testing phases start date | Statement number and date | |
| Ongoing joint testings: | |||
| Refusal to share prescription information | 1. Ongoing, 20.2.2018 | ||
| Accepted joint testings: | |||
| Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9 | 20142017 / 14.3.2017 |
1 = Testing between system supplier and Kela, 2 = Testing between client test organisation and Kela, 3 = Cross-testing.
DynamicHealth / Tieto Healthcare & Welfare Oy
| Registration, return date of pre-test cases | Testing phases start date | Statement number and date | |
| Ongoing joint testings: | |||
| No ongoing joint testings | |||
| Accepted joint testings: | |||
| Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information | 20032016 / 30.12.2016 | ||
| Forward compatibility of the functionality to act on behalf of a minor | - / 12.3.2020 |
Effica / Tieto Healthcare & Welfare Oy
| Registration, return date of pre-test cases | Testing phases start date | Statement number and date | |
| Ongoing joint testings: | |||
| No ongoing joint testings | |||
| Accepted joint testings: | |||
| Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information | 20032016 / 9.12.2016 |
Epic / Epic Helsinki Oy
| Registration, return date of pre-test cases | Testing phases start date | Statement number and date | |
| Ongoing joint testings: | |||
| No ongoing joint testings | |||
| Accepted joint testings: | |||
| Prescription's MR and CDA R2 specifications 3.42 and requirement specifications 2.9, Refusal to share prescription information | 20022018 / 5.10.2018 | ||
| Forward compatibility of the functionality to act on behalf of a minor | - / 7.9.2020 |
eRA / Atostek Oy
| Registration, return date of pre-test cases | Testing phases start date | Statement number and date | |
| Ongoing joint testings: | |||
| No ongoing joint testings | |||
| Accepted joint testings: | |||
| Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information | 20092016 / 29.12.2016 | ||
| Functionality for action on behalf of a minor | 20032020 / 16.3.2020 | ||
| Functionality for action on behalf of a minor (testing of system changes) | 20052020 / 10.8.2020 |
ESKO / PPSHP
| Registration, return date of pre-test cases | Testing phases start date | Statement number and date | |
| Ongoing joint testings: | |||
| No ongoing joint testings | |||
| Accepted joint testings: | |||
| Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information | 20022016 / 9.12.2016 | ||
| Forward compatibility of the functionality to act on behalf of a minor | - / 7.5.2020 |
GFS / CGI Oy
| Registration, return date of pre-test cases | Testing phases start date | Statement number and date | |
| Ongoing joint testings: | |||
| Functionality for action on behalf of a minor | 17.6.2020 | 1. Not started 2. Not tested 3. Not tested | |
| Accepted joint testings: | |||
| Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information | - / 25.11.2016 | ||
| Forward compatibility of the functionality to act on behalf of a minor | - / 6.2.2020 |
1 = Testing between system supplier and Kela, 2 = Testing between client test organisation and Kela, 3 = Cross-testing.
Hilkka / FastROI Oy
| Registration, return date of pre-test cases | Testing phases start date | Statement number and date | |
| Ongoing joint testings: | |||
| No ongoing joint testings | |||
| Accepted joint testings: | |||
| Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9 | 20082016 / 30.12.2016 | ||
| Refusal to share prescription information | 20012018 / 11.1.2018 | ||
| Forward compatibility of the functionality to act on behalf of a minor | - / 16.4.2020 |
Kelain / Kela
| Registration, return date of pre-test cases | Testing phases start date | Statement number and date | |
| Ongoing joint testings: | |||
| No ongoing joint testings | |||
| Accepted joint testings: | |||
| Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9 | 20042016 / 9.12.2016 | ||
| Refusal to share prescription information | 20202017 / 1.6.2017 | ||
| Functionality for action on behalf of a minor | 20012020 / 14.1.2020 |
Lifecare /Tieto Healthcare & Welfare Oy
| Registration, return date of pre-test cases | Testing phases start date | Statement number and date | |
| Ongoing joint testings: | |||
| No ongoing joint testings | |||
| Accepted joint testings: | |||
| Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information | 20192017 / 11.5.2017 | ||
| Forward compatibility of the functionality to act on behalf of a minor | - / 14.2.2020 |
MAXX /Receptum Oy
Pharmacy system
| Registration, return date of pre-test cases | Testing phases start date | Statement number and date | |
| Ongoing joint testings: | |||
| Functionality for action on behalf of a minor | 8.4.2020 | 1. Ongoing, 17.4.2020 2. Not tested 3. Not tested | |
| Accepted joint testings: | |||
| Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information | 20122017 / 11.1.2017 | ||
| Cross-border prescription | 20012019 / 30.9.2019 |
1 = Testing between system supplier and Kela, 2 = Testing between client test organisation and Kela, 3 = Cross-testing.
Mediatri / Mediconsult Oy
| Registration, return date of pre-test cases | Testing phases start date | Statement number and date | |
| Ongoing joint testings: | |||
| Functionality for action on behalf of a minor | 9.6.2020 | 1. Ongoing, 3.7.2020 | |
| Accepted joint testings: | |||
| Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9 | 20072016 / 30.12.2016 | ||
| Refusal to share prescription information | 20212017 / 5.6.2017 | ||
| Forward compatibility of the functionality to act on behalf of a minor | - / 5.5.2020 |
1 = Testing between system supplier and Kela, 2 = Testing between client test organisation and Kela, 3 = Cross-testing.
Mediresepti / Mediconsult Oy
| Registration, return date of pre-test cases | Testing phases start date | Statement number and date | |
| Ongoing joint testings: | |||
| No ongoing joint testings | |||
| Accepted joint testings: | |||
| Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9 | 20132016 / 30.12.2016 | ||
| Refusal to share prescription information | 20222017 / 4.12.2017 | ||
| Forward compatibility of the functionality to act on behalf of a minor | - / 8.5.2020 |
Navitas / Elisa Appelsiini Oy
| Registration, return date of pre-test cases | Testing phases start date | Statement number and date | |
| Ongoing joint testings: | |||
| No ongoing joint testings | |||
| Accepted joint testings: | |||
| Refusal to share prescription information | 20182017 / 24.2.2017 |
pd3 / Pharmadata Oy
Pharmacy system
| Registration, return date of pre-test cases | Testing phases start date | Statement number and date | |
| Ongoing joint testings: | |||
| No ongoing joint testings | |||
| Accepted joint testings: | |||
| Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information | 20172017 / 27.1.2017 | ||
| Cross-border prescription | 20022020 / 20.2.2020 |
Pegasos / CGI Oy
| Registration, return date of pre-test cases | Testing phases start date | Statement number and date | |
| Ongoing joint testings: | |||
| No ongoing joint testings | |||
| Accepted joint testings: | |||
| Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information | 20052016 / 20.12.2016 | ||
| Forward compatibility of the functionality to act on behalf of a minor | - / 8.4.2020 |
Salix / Pharmadata Oy
Pharmacy system
| Registration, return date of pre-test cases | Testing phases start date | Statement number and date | |
| Ongoing joint testings: | |||
| No ongoing joint testings | |||
| Accepted joint testings: | |||
| Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information | 20162017 / 27.1.2017 | ||
| Cross-border prescription | 20022019 / 10.12.2019 |
SoftMedic / CGI Oy
| Registration, return date of pre-test cases | Testing phases start date | Statement number and date | |
| Ongoing joint testings: | |||
| No ongoing joint testings | |||
| Accepted joint testings: | |||
| Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information | - / 22.11.2016 | ||
| Forward compatibility of the functionality to act on behalf of a minor | - / 10.9.2020 |
Uranus / CGI Oy
| Registration, return date of pre-test cases | Testing phases start date | Statement number and date | |
| Ongoing joint testings: | |||
| Functionality for action on behalf of a minor | 15.7.2020 | 1. Not started 2. Not tested 3. Not tested | |
| Accepted joint testings: | |||
| Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information | 20152017 / 11.1.2017 | ||
| Forward compatibility of the functionality to act on behalf of a minor | - / 14.1.2020 |
1 = Testing between system supplier and Kela, 2 = Testing between client test organisation and Kela, 3 = Cross-testing.